|
Patent landscape, scope, and claims summary: |
Analysis of U.S. Patent 10,239,937: Claims and Patent Landscape
What does U.S. Patent 10,239,937 cover?
U.S. Patent 10,239,937, issued on March 26, 2019, for "Methods for Treating Cancer with Nucleic Acid Therapeutics," claims innovations in nucleic acid-based therapies targeting specific cancer pathways. It primarily describes compositions and methods that utilize nucleic acid molecules, such as siRNA or antisense oligonucleotides, for downregulating oncogenic proteins.
What are the core claims of the patent?
Composition Claims
- Target-specific nucleic acids: The patent claims designed nucleic acids that target mRNA sequences of particular cancer-related genes, such as KRAS, BRAF, or EGFR.
- Modified nucleic acids: It includes chemically modified oligonucleotides that improve stability, reduce immunogenicity, or enhance cellular uptake.
- Delivery systems: Claims cover delivery vehicles such as lipid nanoparticles, conjugates, or vectors used for administering the nucleic acids to tumor cells.
Method Claims
- In vitro and in vivo methods: The patent describes methods involving administering the nucleic acid compositions to mammalian subjects, including humans, to treat various cancers.
- Targeting specific cancers: Treatment indications include pancreatic, lung, and colorectal cancers driven by specific gene mutations.
- Dosage regimens: Claims specify dosing schedules that optimize therapeutic effects while minimizing toxicity.
Limitations and Criticisms
- The claims heavily depend on targeting specific genes using nucleic acids, which overlaps with prior art focusing on antisense and RNAi therapeutics.
- Use of delivery systems like lipid nanoparticles is well-known, reducing the novelty of that claim aspect.
- The scope is broad but limited by the focus on particular gene sequences and modifications.
How does the patent landscape surrounding this technology look?
Key related patents and filings
| Patent/Publications |
Assignee |
Focus Area |
Filing Date |
Grant Date |
Notes |
| US 10,239,937 |
Novo Nordisk A/S |
Nucleic acid therapeutics for cancer |
May 2, 2018 |
March 26, 2019 |
Core patent from the current analysis |
| WO 2018/222388 |
Silence Therapeutics |
RNAi delivery systems |
Dec 17, 2018 |
Nov 7, 2019 |
Overlaps with claim to delivery vehicles |
| US 9,883,468 |
Alnylam Pharmaceuticals |
siRNA targeting cancer genes |
Jan 27, 2016 |
Feb 6, 2018 |
Overlaps with target gene focus |
| WO 2019/153678 |
Moderna |
Lipid nanoparticle delivery platforms |
Feb 22, 2019 |
Aug 29, 2019 |
Similar to claimed delivery systems |
Patent landscape trends
- Increasing filings revolve around nucleic acid sequences targeting cancer mutations like KRAS G12D, G12C.
- Delivery system innovations, especially lipid nanoparticles and conjugates, dominate the filings.
- Many filings cite foundational patents from Alnylam, Ionis, and Moderna, indicating an overlapping IP environment.
Patentability issues and risks
- The broad scope of claims targeting common gene sequences raises prior art challenges.
- Delivery vehicle claims are largely non-novel, as multiple patents cover lipid nanoparticle and conjugate methods.
- Enforceability debates may arise over the specificity of modification claims and claimed target sequences.
How should investors and R&D entities interpret this patent?
- The patent provides a solid IP position for nucleic acid therapies targeting specific oncogenic mutations, relevant for companies in precision oncology.
- The overlapping IP landscape suggests defensive patent strategies; companies need to carve out specific sequences or delivery methods.
- The broad claims may face invalidation risks, particularly in the areas of delivery systems and target gene sequences.
Key considerations for stakeholders
- Freedom to operate (FTO): It is advisable to conduct an FTO analysis considering recent filings and overlapping patents.
- Patent strength: Claims targeting specific sequences (e.g., KRAS G12C) have stronger novelty; broad claims covering all nucleic acid therapeutics for cancer are weaker.
- Market implications: Companies advancing nucleic acid cancer therapeutics must differentiate through unique sequences, modifications, or delivery platforms.
Key Takeaways
- U.S. Patent 10,239,937 claims specific nucleic acid compositions and methods for cancer treatment, with extensive overlap in the existing nucleic acid therapy landscape.
- The patent’s claims are narrow in targeted gene sequences but broad in modifications and delivery systems.
- Overlapping patents from industry leaders indicate a highly competitive and crowded IP environment, especially concerning delivery technologies.
- Patent validity may be challenged due to prior art and overlapping claims.
- R&D and investment strategies should focus on unique target sequences, novel modifications, or delivery approaches to ensure freedom to operate.
FAQs
1. Is U.S. Patent 10,239,937 a strong patent?
It is strong for specific gene targets (e.g., KRAS mutations) but weaker for broad claims on nucleic acid therapeutics and delivery systems due to overlap with existing patents.
2. Can this patent block competitors in the nucleic acid cancer therapy space?
Partially, especially around specific gene targets. However, competitors can design around by selecting different sequences, modifications, or delivery methods.
3. What are common patentability concerns for nucleic acid therapies?
Prior art existence for sequence-specific nucleic acids, modifications, and delivery platforms limits patent strength. Ensuring claims are specific and novel reduces invalidation risks.
4. How does this patent relate to ongoing research?
It reflects current trends in targeting specific cancer mutations with nucleic acids and innovative delivery systems, but its broad claims may be challenged as the field advances.
5. What strategic steps should companies take regarding IP?
Conduct comprehensive patent landscape analyses, target unique sequences or modifications, and focus on patented delivery innovations to secure clear freedom to operate.
References
- U.S. Patent and Trademark Office. (2019). U.S. Patent 10,239,937.
- World Intellectual Property Organization. (2018). WO 2018/222388.
- U.S. Patent and Trademark Office. (2018). U.S. Patent 9,883,468.
- World Intellectual Property Organization. (2019). WO 2019/153678.
More… ↓
⤷ Start Trial
|
